Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects

• US 20070254858A1
• Filed: 08/07/2006
• Published: 11/01/2007
• Est. Priority Date: 04/27/2006
• Status: Abandoned Application

• Current Assignee: Peter J. Cronk
• Original Assignee: Peter J. Cronk
• Inventors: Cronk, Peter J.
• Application Number:
  US11/462,762
• Publication Number:
  US 20070254858A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/203 Retinoic acids ; Salts thereof
• CPC Class Codes: A61K 31/567 substituted in position 17 alpha, e.g. mestranol, norethandrolone
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Abstract

The present invention provides pharmaceutical compositions for the treatment of acne, psychotic illnesses, such as schizophrenia, cancer, such as cancer of the head, neck and lung, and emphysema, comprising co-administering a therapeutically effective amount of isotretinoin and a contraceptive in a contraceptively effective dosage. The contraceptive preferably does not contain 100 wt % progestogen. Methods of treating acne and unit dosage delivery systems are also provided. Also provided is an improved method of treating acne, and other diseases, comprising providing a blister pack comprising at least about 28 separate daily dosage units of a therapeutically effective amount of isotretinoin, or other retinoic acid derivative equivalent, and at least about 21-28 additional daily dosage units of an oral contraceptive in a contraceptively effective amount, selected from the group consisting essentially of: estrogen, estrogen and progestogen, mifepristone, or a combination thereof, whereby for at least about 21 successive days, said oral dosage unit of isotretinoin, or other retinoic acid derivative equivalent, and said oral dosage unit of said oral contraceptive are administered to a female of child-bearing age. Patch, inhaler, nebulizer, and injection formulations for the preferred active ingredients are also provided.

Claims

1. An improved method of treating acne comprising providing a blister pack comprising at least about 28 separate daily dosage units of a therapeutically effective amount of isotretinoin or other retinoic acid derivative equivalent, and at least about 21-28 additional daily dosage units of an oral contraceptive in a contraceptively effective amount selected from the group consisting of:

estrogen, estrogen and progestogen, mifepristone, or a combination thereof, whereby for at least about 21 successive days, said oral dosage unit of isotretinoin or other retinoic acid derivative equivalent and said oral dosage unit of said oral contraceptive are administered to a female of child bearing age.

2. The method of claim 1 wherein said blister pack comprises at least about 77-84 separate compartments, comprising at least about 56 separate daily dosage units of isotretinoin or other retinoic acid derivative equivalent.

3. The method of claim 1 wherein said blister pack provides compartments for the administration of said isotretinoin or other retinoic acid derivative equivalent, and separate compartments for the administration of said oral contraceptive.

4. The method of claim 1 wherein said isotretinoin or other retinoic acid derivative equivalent and said oral contraceptive are provided in separate dosage units for said at least about 21 days, followed by a period of 4-8 days in which only said isotretinoin or other retinoic acid derivative equivalent dosage units are provided.

5. The method of claim 1 wherein said at least about 28 separate daily dosage units of isotretinoin comprise about 0.1-3.0 mg/kg of body weight, or about 20-80 milligrams in daily unit form.

6. The method of claim 2 wherein said at least 56 separate daily dosage units of isotretinoin or other retinoic acid derivative equivalent comprise about 0.05-1.5 mg/kg of body weight, or about 10-40 milligrams in a bi-daily unit form.

7. A pharmaceutical blister pack having dosage units arranged sequentially and comprising:

a first phase comprising at least about 21 daily dosage units of an oral contraceptive, and at least about 21 daily dosage units of isotretinoin or other retinoic acid derivative equivalent; and

a second phase of about 4-8 daily dosage units of isotretinoin or other retinoic acid derivative equivalent.

8. The pharmaceutical blister pack of claim 7 wherein said oral contraceptive does not contain 100% progestogen.

9. The pharmaceutical blister pack of claim 8, wherein each of said daily dosage of isotretinoin, or other retinoic acid derivative equivalent, comprises a bi-daily administration containing 2 units.

10. A pharmaceutical packaging comprising dosage units arranged sequentially and comprising a first phase comprising 21 separate daily dosage units of an oral contraceptive which do not contain 100% progestogen, and at least about 21 separate daily dosage units of isotretinoin, or other retinoic acid derivative equivalent, and a second phase comprising at least about 4-8 separate daily dosage units of isotretinoin, or other retinoic acid derivative equivalent.

11. The pharmaceutical package of claim 10 further comprising 4-8 placebos arranged to be taken with said 4-8 separate daily dosage units of said isotretinoin, or other retinoic acid derivative equivalent of said second phase.

12. A pharmaceutical packaging comprising dosage units arranged sequentially and comprising a first phase comprising 21-28 separate daily dosage units of an oral contraceptive in a contraceptively effective amount, which does not contain 100% progestogen, and at least about 21-56 separate daily dosage units of isotretinoin, or other retinoic acid derivative equivalent, in a therapeutically effective amount.

13. The pharmaceutical package of claim 12 comprising at least 56 separate daily dosage units of isotretinoin, or other retinoic acid derivative equivalent, and arranged for bi-daily administration.

14. The pharmaceutical package of claim 12 wherein at least 28 separate daily dosage units of said oral contraceptive are provided.

15. A pharmaceutical packaging comprising dosage units arranged sequentially and comprising a first phase comprising 21 separate dosage units of an oral contraceptive in a contraceptively effective amount which do not contain 100% progestogen, in admixture, with isotretinoin, or other retinoic acid derivative equivalent, in a therapeutically effective amount, and a second phase comprising at least about 4-8 separate dosage units of isotretinoin or other retinoic acid derivative equivalent in a therapeutically effective amount.

16. The pharmaceutical package of claim 15 wherein said oral contraceptive comprises a contraceptive selected from the group consisting of:

estrogen, estrogen and progestogen, mifepristone, or a combination thereof.

17. A pharmaceutical packaging comprising dosage units arranged sequentially and comprising a first phase comprising 21 separate dosage units of an oral contraceptive in a contraceptively effective amount which does not contain 100% progestogen, and at least about 21 separate dosages units of isotretinoin, or other retinoic acid derivative equivalent, in a therapeutically effective amount, and a second phase comprising at least about 4-8 separate dosage units of isotretinoin, or other retinoic acid derivative equivalent, in a therapeutically effective amount, without oral contraceptive administration.

18. The pharmaceutical packaging of claim 17 wherein said separate dosage units of oral contraceptive and isotretinoin, or other retinoic acid derivative equivalent, are provided in daily dosages for a 21 day sequential period.

19. A method of treating acne comprising providing a transdermal patch comprising a therapeutically effective amount of isotretinoin or other retinoic acid derivative equivalent in a therapeutically effective amount and a transdermal contraceptive in a contraceptively effective amount.

20. The method of claim 19, wherein said patch is worn for about 5-9 days prior to replacement.

21. The method of claim 19, wherein said patch delivers its medication via a single-layer drug-in-adhesive, multi-layer drug-in-adhesive, reservoir, matrix type system, microstructured transdermal system or a combination thereof.

22. A medicated transdermal patch comprising,

a time released drug formulation comprising a therapeutically effective amount of isotretinoin or other retinoic acid derivative equivalent and a transdermal contraceptive in a contraceptively effective amount.

23. The transdermal patch of claim 22, wherein said patch comprises a transdermal system selected from the group consisting of:

single-layer drug-in-adhesive, multi-layer drug-in-adhesive, reservoir, matrix type, microstructured transdermal system or a combination thereof.

24. The transdermal patch of claim 22, wherein said isotretinoin or other retinoic acid derivative equivalent and transdermal contraceptive are administered simultaneously.

25. The transdermal patch of claim 22, wherein said isotretinoin or other retinoic acid derivative equivalent and transdermal contraceptive are administered consecutively.

26. The transdermal patch of claim 22, wherein said isotretinoin or other retinoic acid derivative equivalent and transdermal contraceptive are administered consecutively via separate drug-in adhesive layers of a multi-layer drug-in-adhesive system for co-administration to a patient.

27. The transdermal patch of claim 22, wherein said isotretinoin or other retinoic acid derivative equivalent and transdermal contraceptive are administered consecutively via a single-layer drug-in-adhesive system for co-administration to a patient.

28. A method of treating or preventing emphysema in a patient comprising co-administering a therapeutically effective amount of isotretinoin and a contraceptively effective dosage of a contraceptive.

29. The method of claim 28 wherein said co-administration is made directly into the lung of said patient by nebulizer, inhaler, or vaporizer.

30. A method of treating or preventing psychotic illness in a patient comprising co-administering a therapeutically effective amount of isotretinoin and a contraceptively effective dosage of a contraceptive.

31. The method of claim 30 wherein said psychotic illness comprises schizophrenia.

32. A method of treating or preventing cancer in a patient comprising co-administering a therapeutically effective amount of isotretinoin and a contraceptively effective dosage of a contraceptive.

33. The method of claim 32 wherein said cancer comprises cancer of the head, neck, lung or a combination thereof.